What’s Up With Organovo Holdings Inc.’s Stock Jump?

A key opinion leader weighs in on the company's first commercial product.

Jun 26, 2014 at 11:02AM

Shares of 3-D bioprinting company Organovo Holdings (NYSEMKT:ONVO) were up as much as 12% this morning on the heels of a key medical conference presentation in Germany. Read below to see how this development may affect your long-term investment thesis.

Screen Shot

Source: Organovo.

Many people believe they key to Organovo's ultimate success is the printing of actual human organs via the company's NovoGen MMX Bioprinter. While that may be a goal over a period of decades, investors are much better off focusing on the company's near-term products: 3-D tissues that pharmaceutical companies can use in drug toxicity tests.

In plain English, if Organovo's 3-D assays can accurately mimic the behavior of native cells; pharmaceutical companies can use these assays to detect toxicities long before expensive FDA trials commence. That would save these companies billions of dollars in the long run.

Organovo cleared early hurdles ahead of schedule: internal functional validation testing was completed two months early in January, and the company began taking a limited number of customers on this spring.

The next "big event" for investors are results and opinions from "key opinion leaders" -- big shots in the scientific community issuing opinions on the advantages of Organovo's 3-D printed tissues, and if they are significantly better than their 2-D and 3-D peers.

Positive news from a key opinion leader
Yesterday, Dr. Adrian Roth, head of mechanistic safety for Roche Pharmaceutical, became  the first key opinion leader to make his findings public. His results, released at the 3D Cell Culture 2014 conference in Germany, were encouraging for Organovo and its investors.

Organovo's press release cited two key findings with regards to its 3-D liver assays showing the appropriate reaction to a known toxin:

  1. "Organovo's 3D Liver system was able to distinguish a toxic drug known to cause drug induced liver injury (DILI) from a close chemical analogue that is known to be non-toxic.
  2. The toxicity of the toxic compound was detected at physiologically relevant doses, an important observation not previously reported with the same compounds in other model liver systems."

Put simply, these assays were accurate enough to distinguish between two compounds that -- though very similar -- have wildly different effects on the liver, and the assays were able to do so at normal dosage levels.

Because many companies already vie to supply such assays to pharmaceutical companies, these results coming from Roche are enormously positive.

However, this doesn't mean investors should load up on Organovo's stock. The company is still highly speculative; though it could have a bright future, it is very difficult to foresee how the competitive landscape may evolve over time, and how much Organovo's assays will yield on the open market if they are successful in the lab.

Though I own shares myself, they make up less than 1% of my overall holdings.

Leaked: This coming blockbuster will make every biotech jealous
Organovo might be a sexy stock to invest in, but its not the only growth company in the health care industry.

Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


Brian Stoffel owns shares of Organovo. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers